Drug Profile
EF 5 - Scotia
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Scotia Holdings [CEASED]
- Class
- Mechanism of Action Prostaglandin synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 04 Jul 2000 Discontinued-III for Rheumatoid arthritis in United Kingdom (PO)
- 25 Mar 1999 No-Development-Reported for Rheumatoid arthritis in United Kingdom (PO)
- 16 Nov 1998 EF 5 is now called EF 5 - Scotia